Related Experiment Videos
Adenosine deaminase (ADA) activity in lymphocytes of normal individuals and patients with chronic lymphatic leukaemia
British Journal of Haematology
|May 1, 1977
Insights
Adenosine deaminase (ADA) activity is significantly lower in lymphocytes from chronic lymphatic leukemia (CLL) patients compared to healthy individuals. This finding may offer insights into CLL pathogenesis and potential diagnostic markers.
Area of Science:
- Biochemistry
- Hematology
- Oncology
Background:
- Chronic lymphatic leukemia (CLL) is a common B-cell malignancy.
- Adenosine deaminase (ADA) is a key enzyme in purine metabolism.
- Altered enzyme activity can be indicative of cellular dysfunction.
Purpose of the Study:
- To investigate adenosine deaminase (ADA) activity in lymphocytes of CLL patients.
- To compare ADA levels in CLL patients with healthy controls.
Main Methods:
- Enzyme activity assay for adenosine deaminase (ADA).
- Analysis of lymphocyte samples from 49 CLL patients and 42 healthy controls.
Main Results:
- Mean ADA activity in normal lymphocytes was 4.35 ± 3.34 µmol/h/10^8 cells.
- Mean ADA activity in CLL lymphocytes was significantly lower at 2.45 ± 2.54 µmol/h/10^8 cells.
Conclusions:
- Lymphocytes in CLL patients exhibit reduced adenosine deaminase (ADA) activity.
- This enzymatic difference could be a potential biomarker for CLL.
Abstract:
Adenosine deaminase (adenosine aminophydrolase, ADA) activity was found to be low in lymphocytes of chronic lymphatic leukaemia (CLL) patients compared to normal lymphocytes. This was determined on 42 controls and 49 CLL patients. The mean activity in normal lymphocytes was found to be 4.35 +/- 3.34 mumol/h/10(8) cells while in CLL cells it was 2.45 +/- 2.54 mumol/h/10(8) cells.